Asperger syndrome is commonly known as Asperger's, is a neurodevelopmental syndrome. People with Asperger syndrome exhibit three major symptoms such as difficulty with social interaction and nonverbal communication, repetitive and restricted patterns of behavior and interests, and standing steady on what they think. These syndromes start during childhood and continue with individuals till they grow up. Asperger syndrome have side effects such as abnormal distractions or ceremonies, redundant practices, issues with social abilities, constrained scope of interests, coordination issues and communication challenges.
Many growth factors such as ongoing technological advancements, rising awareness programs by the various government across the globe for autism alertness and occurrence of autism related complications, are propelling the growth of the market across the globe. Likewise, growing generic pharmaceutical production, growing patient numbers, increasing healthcare funding, changing lifestyle of the people, improving regulatory guidelines are likely to impel market growth during the forecast period. However, stringent FDA controls is major restraining factor that could hamper the market growth.
The study analyses Global Asperger syndrome market based on diagnosis, treatment, end user and geography.
Based on diagnosis, differential diagnosis segment is expected to boost market growth during the forecast period. Increasing preference towards differential diagnosis method for the treatment of Asperger syndrome is escalating the growth of the market. The differential diagnosis include nonverbal learning disorder, major depressive disorder, personality disorder, stereotypic movement disorder, obsessive-compulsive disorder, social anxiety disorder, bipolar disorder, pragmatic semantic disorder, and others.
Based on treatment, medication segment is projected to witness high growth during the estimated timeframe. Till now, there were not any drugs that approved by the FDA for the treatment for Asperger's or autism spectrum disorders. But some medications such as antipsychotic drugs, sychiatric agents, selective serotonin reuptake inhibitors, and others can help with related symptoms like anxiety and depression. Antipsychotics include aripiprazole, paliperidone, and risperidone. The U.S. FDA recently approved risperidone for the treatment of irritability in adolescents and children with autism. As this is the first drug approved for use in autism, this approval is noteworthy.
Based on end user, hospital and clinic segments are likely to contribute to the growth of the market. An increasing number of hospitals and care centers that provide treatment for the Asperger syndrome is major driving factor behind the growth of the market. Additionally, factors such as rising occurrence of Asperger syndrome in children, improved treatment provided by the hospitals to Asperger patient and rising preference of the patients for treatment in these settings are expected to boost growth of the market.
Geographically, the study is comprised of the key countries of North America, Europe, Asia-Pacific and Rest of the World. North America held the largest market share of global asperger syndrome market and is likely to dominate the market over the estimated time frame. The major factors such as a rising incidence of autism spectrum disorders and associated complications, growing initiatives and investment by the pharmaceutical companies to produce novel and effective drugs, increasing technological advancements and improving adoption rate of various treatments to help patients with asperger syndrome are accredited to the market growth across the region.
The major key players of market includes Eli Lilly and company, Shire, Jazz Pharmaceuticals, Pfizer, GlaxoSmithKline, Forest laboratories, Johnson & Johnson, Bristol-Myers Squibb, Otsuka pharmaceutical, AstraZeneca, Allergan, AbbVie Inc, and Roche Holding AG among others.
The study analyses global Asperger Syndrome market based on diagnosis, treatment, end user, and geography. Asperger Syndrome market by diagnosis is segmented into DSM-IV, differential diagnosis, gilliam Asperger’s disorder scale (GADS), childhood asperger syndrome test, krug asperger’s disorder index (KADI). The differential diagnosis segment is likely to dominate the market over the forecast period. By treatment, the market is segmented into parent education and training, social skills training, speech-language therapy, sensory integration/occupational therapy, and medication. The medication segment is likely to dominate market during the forecast period owing to rising adoption of medications to treat this syndrome. Based on end user, the market is segmented into hospitals, clinics, diagnostics centers, drug stores, and pharmacies. The hospital segment is likely to register fastest growth in years to come owing to rising preference of the individuals towards hospitals to treat Asperger syndrome. Geographically, the study is comprised of the key countries of North America, Europe, Asia-Pacific and Rest of the World.
Why to buy this report: